AEON AEON Biopharma, Inc.

XASE
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

AEON — —

What changed

Recent filings, trades and moves
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XASE
Market Cap
$0.0B
Employees
8
List Date
2023-07-24
CIK
0001837607
Next Earnings
2026-11-13
EPS Forecast
($0.10)
Headquarters
Aliso Viejo, CA
Homepage
https://www.aeonbiopharma.com

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'23'24'25'26Avg
Jan---2.96%-76.59%4.50%-25.02%
Feb--66.67%-91.99%-3.45%-9.59%
Mar---9.73%-5.00%-7.08%-7.27%
Apr---48.18%-27.06%-5.66%-26.97%
May---55.74%31.81%-14.98%-12.97%
Jun---35.98%38.03%-4.09%-0.68%
Jul-14.67%65.38%-8.77%-58.63%-4.17%
Aug-31.54%-27.52%7.65%0.31%-12.78%
Sep6.06%24.70%8.83%8.46%12.01%
Oct-9.43%-10.00%6.25%-5.52%-4.67%
Nov9.85%-38.19%-6.92%-33.41%*-17.17%
Dec19.01%-10.70%39.33%--15.88%
Total-26.64%-84.08%-96.52%-79.58%-71.70%
* Only 4 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.23
SMA 50: $0.26
SMA 200: $0.65
Current: $0.18
EMA 12: $0.22
EMA 26: $0.24
MACD: -0.0189 | Signal: -0.0082
BEARISH
ADX (14): 27.05
TREND
+DI: 20.48
−DI: 32.18

Momentum Oscillators

RSI (14): 37.11
NEUTRAL
Stoch %K: 24.51
Stoch %D: 15.03
Williams %R: -70.09

Volume & Volatility

BB Upper: $0.30
BB Lower: $0.17
NEUTRAL
OBV: 515,946,994
Vol SMA 20: 973,080
Vol ROC: 369.49%
ATR: $0.03
True Range: $0.02
HV 20: 155.8%
HV 30: 146.2%
HV 60: 142.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before AEON’s Aug 11 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

SYMBOL: AEON

Executive Summary

Overall Assessment: NEUTRAL (confidence level 6/10)

Key Drivers: Recent debt swap agreement with Daewoong, positive earnings trend, low volatility

Primary Risks: Potential for further market volatility, limited options activity data available

Investment Thesis: AEON's recent debt swap agreement with Daewoong may have stabilized the company's financial situation, while its positive earnings trend and low volatility make it an attractive investment opportunity. However, the lack of options activity data and potential market volatility remain concerns.

Recent News Sentiment Impact: The sentiment surrounding the debt swap agreement is mixed, with two positive headlines and one negative headline. This ambiguity may have contributed to AEON's neutral technical signals.

Technical Analysis

Trend Direction: Medium-term (1-3 months) downtrend, short-term (1-4 weeks) consolidation

Support/Resistance Levels:

  • SMA 20: $0.81 (support)
  • SMA 50: $0.92 (resistance)
  • Upper Bollinger Band: $0.95 (resistance)

Momentum Signals:

  • RSI (14): 52.98 (neutral, indicating no clear buy or sell signal)
  • MACD: -0.03 / Signal: 0.01 / Histogram: -0.04 (bearish momentum signal)

Volume Analysis: Volume SMA 20 is trending upwards, suggesting increasing institutional interest.

News & Sentiment Analysis

Recent Headlines Summary: AEON's debt swap agreement with Daewoong has been a dominant theme in recent news headlines, with mixed sentiment and no clear consensus on its impact.

Sentiment Assessment: Aggregate news sentiment is NEUTRAL (50% positive, 25% negative, 25% neutral).

Catalyst Identification: Upcoming earnings release date: 2025-08-12

Market Narrative: The recent debt swap agreement may have stabilized AEON's financial situation, but the company's technical signals remain neutral. The market is likely waiting for further guidance from upcoming earnings.

Risk & Volatility Assessment

Beta Interpretation: Low risk relative to market (beta 0.29), indicating low volatility.

Volatility Regime: Current vs historical volatility levels: relatively low volatility.

Options Market Signals: No options data available, making it difficult to assess potential for price movements.

Downside Protection: SMA 20 provides support at $0.81, with the lower Bollinger Band offering additional protection at $0.68.

Market Context & Positioning

Sector Performance: AEON's sector (Healthcare) is performing relatively well, with a slight decline in recent weeks.

Institutional Activity: Volume SMA 20 indicates increasing institutional interest.

Correlation Analysis: AEON's correlation with the market (SPY) is low at 0.03, suggesting minimal dependence on market movements.

Relative Valuation: AEON's current price is trading within a relatively narrow range, making it difficult to assess its relative valuation.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $0.81 (support)
  • Upper Bollinger Band: $0.95 (resistance)

Breakout/Breakdown Levels: SMA 50 at $0.92 may act as resistance, while the lower Bollinger Band at $0.68 may provide support.

Time-Sensitive Catalysts: Upcoming earnings release date: 2025-08-12

Risk Management: Stop-loss levels should be set at $0.68 to protect against potential downside risks, with position sizing considerations based on individual risk tolerance.

Generated

AEON Options Activity & IV Rank

Loading options activity...
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.0819
Alpha: -111.84%
Correlation: 0.1354
R-Squared: 1.8%
Stock Volatility: 109.9%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time

AEON Institutional Ownership (13F)

Filings for 2026-06-30 · 10 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

21 filers12,789,407 shares$9.15M value
# Filer Shares Value % of Total % of Float Period
1 Dauntless Investment Group, LLC 12,490,154 $8.98M 98.20% — 2026-06-30
2 Vanguard Capital Management LLC 90,529 $65.09K 0.71% — 2026-06-30
3 Blue Owl Capital Holdings LP 42,353 $30.49K 0.33% — 2026-06-30
4 Geode Capital Management, LLC Custodian 95,311 $28.59K 0.31% — 2026-09-30
5 Formidable Asset Management, LLC 20,024 $14.40K 0.16% — 2026-09-30
6 Vanguard Fiduciary Trust Co 13,713 $9.86K 0.11% — 2026-06-30
7 Beacon Wealthcare LLC 12,856 $3.86K 0.04% — 2026-09-30
8 UBS Group AG Custodian 5,062 $3.64K 0.04% — 2026-06-30
9 LPL Financial LLC Custodian 11,500 $3.45K 0.04% — 2026-09-30
10 BlackRock, Inc. Custodian 2,834 $2.04K 0.02% — 2026-06-30
11 Tower Research Capital LLC (TRC) Custodian 2,567 $1.85K 0.02% — 2026-06-30
12 Steward Partners Investment Advisory, LLC 1,100 $791 <0.01% — 2026-06-30
13 WOLFF WIESE MAGANA LLC 567 $171 <0.01% — 2026-09-30
14 Morgan Stanley Custodian 150 $108 <0.01% — 2026-06-30
15 SBI Securities Co., Ltd. 329 $99 <0.01% — 2026-09-30
16 Wells Fargo & Company Custodian 90 $65 <0.01% — 2026-06-30
17 DUPONT CAPITAL MANAGEMENT CORP 170 $51 <0.01% — 2026-09-30
18 GHP Investment Advisors, Inc. 95 $29 <0.01% — 2026-09-30
19 DANSKE BANK A/S 1 $1 0.00% — 2026-06-30
20 Barclays PLC Custodian 1 $0 0.00% — 2026-09-30
21 Caitong International Asset Management Co., Ltd 1 $0 0.00% — 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

AEON Insider Trading (Form 4)

Latest: 2026-08-21
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-21 Timothy P Lynch 10%+ Owner Buy (P) +1,150,000 $0.21 $243.5K EDGAR
2026-06-22 Shelley B Thunen Director Award (A) +222,684 — EDGAR
2026-06-22 Jost Fischer Director Award (A) +222,684 — EDGAR
2026-06-22 Robert J Palmisano Director Award (A) +222,684 — EDGAR
2026-06-22 Marc Forth Director Award (A) +222,684 — EDGAR
2026-06-22 Eric G Carter Director Award (A) +222,684 — EDGAR
2026-04-03 John Bencich CHIEF FINANCIAL OFFICER Award (A) +754,717 — EDGAR
2026-03-11 Chad Oh CHIEF MEDICAL OFFICER Award (A) +2,179,372 — EDGAR
2026-03-05 Alexander Blair Wilson CLO, CSO, and Corp Secretary Award (A) +2,179,372 — EDGAR
2026-03-05 Jennifer Sy PRINCIPAL ACCOUNTING OFFICER Award (A) +1,500,925 — EDGAR
2026-02-19 Robert E. Bancroft PRESIDENT & CEO Award (A) +3,000,000 — EDGAR
2025-05-23 Robert J Palmisano Director Grant (A) +308,641 RSU — EDGAR
2025-05-23 Jost Fischer Director Buy (P) +60,000 $0.49 $29.2K EDGAR
2025-05-23 Marc Forth Director Grant (A) +370,370 RSU — EDGAR
2025-05-23 Shelley B Thunen Director Grant (A) +308,641 RSU — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

AEON Insider Holdings

11 insiders · @ $0.18
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Timothy P Lynch 10%+ Owner 6,500,000 $1.18M $243.5K 1 2026-08-21
2 Robert E. Bancroft PRESIDENT & CEO 3,177,103 $577.6K $0 3 2026-02-19
3 Alexander Blair Wilson CLO, CSO, and Corp Secretary 2,183,005 $396.9K $0 3 2026-03-05
4 Marc Forth CHIEF EXECTUIVE OFFICER 973,231 $176.9K $0 3 2026-06-22
5 Chad Oh CHIEF MEDICAL OFFICER 866,564 $157.5K $0 3 2026-03-11
6 John Bencich CHIEF FINANCIAL OFFICER 754,717 $137.2K $0 1 2026-04-03
7 Jennifer Sy PRINCIPAL ACCOUNTING OFFICER 575,251 $104.6K $0 3 2026-03-05
8 Jost Fischer Director 489,469 $89.0K $84.5K 5 2026-06-22
9 Robert J Palmisano Director 290,163 $52.8K $0 4 2026-06-22
10 Shelley B Thunen Director 258,705 $47.0K $0 3 2026-06-22
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

AEON Board & Officers

As of SEC filings through Aug 21, 2026

Directors 7

Officers 5

10% owners 2

Changes in the last 10 years (39)
Aug 19, 2026Timothy P Lynch became a 10% owner
Apr 1, 2026John Bencich became Chief Financial Officer
May 23, 2025Marc Forth no longer listed as Chief Exectuive Officer in SEC filings
Apr 29, 2025Robert E. Bancroft became a director
Apr 29, 2025Robert E. Bancroft became President & CEO
Sep 4, 2024Robert J Palmisano no longer listed as a 10% owner in SEC filings
May 17, 2024Jennifer Sy became Principal Accounting Officer
May 16, 2024The company announced the departure of Peter A Reynolds as Chief Financial Officer in an SEC filing
Apr 12, 2024Seongsoo Park became a director
Mar 21, 2024Marc Forth listed as Chief Exectuive Officer (previously Chief Executive Officer) in SEC filings
Aug 14, 2023Strathspey Crown Holdings Group, LLC reported in an SEC filing no longer being a 10% owner
Jul 26, 2023Robert J Palmisano no longer listed as CEO in SEC filings
Jul 21, 2023Strathspey Crown Holdings Group, LLC became a 10% owner
Jul 21, 2023Shelley B Thunen became a director
Jul 21, 2023Peter A Reynolds became Chief Financial Officer
Jul 21, 2023Marc Forth became a director
Jul 21, 2023Marc Forth became Chief Executive Officer
Jul 21, 2023Jost Fischer became a director
Jul 21, 2023Eric G Carter became a director
Jul 21, 2023Daewoong Co., Ltd became a 10% owner
Not reported recently (7)
  • Priveterra Sponsor, LLC · Last reported as a 10% owner in an SEC filing dated Jul 26, 2023
  • Oleg Grodnensky · Last reported as a 10% owner in an SEC filing dated Jul 26, 2023
  • Vikram Malik · Last reported as a 10% owner in an SEC filing dated Jul 26, 2023
  • David Meredith · Last reported as Chief Legal Officer&Secretary in an SEC filing dated Feb 8, 2021
  • Lance A Berry · Last reported as a director in an SEC filing dated Feb 8, 2021
  • Julie Andrews · Last reported as a director in an SEC filing dated Feb 8, 2021
  • James Lightman · Last reported as a director in an SEC filing dated Feb 8, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

AEON Proposed Insider Sales (Form 144)

Latest: 2024-07-29
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-07-29 Oleg Grodnensky Affiliate 201,825 $530.8K 2024-07-29 J.P. Morgan Securities LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-03 Material agreement EDGAR
2026-10-23 Regulation FD disclosure EDGAR
2026-09-30 Regulation FD disclosure · Other events EDGAR
2026-08-12 Earnings results · Regulation FD disclosure EDGAR
2026-08-03 Regulation FD disclosure · Other events EDGAR
2026-07-23 Other events EDGAR
2026-07-15 Material agreement · Other events EDGAR
2026-06-17 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-08-12 0001837607-26-000062 EDGAR
ETF Holders
3 ETFs hold AEON
3 shown · $3.25M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 SPEM State Street® SPDR® Portfolio Emerging Markets ETF SPDR (State Street) 0.02% $3.0M $16.2B 2026-11-05
2 EWX State Street® SPDR® S&P® Emerging Markets Small Cap ETF SPDR (State Street) 0.03% $196,851 $614.4M 2026-11-05
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $27,159 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

AEON vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 45.8 +45.5% +30.7% 27
JNJ Johnson & Johnson $664.9B 42.8 +7.8% +36.1% 54
ABBV ABBVIE INC. $514.9B 50.5 +10.7% +27.9% 30
MRK Merck & Co., Inc. $361.7B 153.4 +4.9% +39.7% 44
NVS Novartis AG $307.0B — — +18.2% 36
AZN AstraZeneca PLC $289.1B — — +106.8% 0
ABT Abbott Laboratories $190.4B 40.9 +10.0% −11.0% 20
NVO Novo-Nordisk A/S $177.7B — — −21.0% 15
AEON AEON Biopharma, Inc. $13M — — −83.6% —
Peer median $334.4B 45.8 +10.0% +29.3% 28

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.